Participated · Series C · Oct 2025

Founded in 2015, Omnix Medical is focused on discovering and developing novel antimicrobial peptide (AMP) therapies that address life-threatening, antibiotic-resistant infections. Its lead candidate, OMN6, rapidly destroys bacterial cell membranes and has received Fast-Track and Qualified Infectious Disease Product designations from the U.S. FDA. The company is currently running Phase II proof-of-concept trials targeting Gram-negative pathogens such as Acinetobacter baumannii, a major cause of hospital-acquired infections. Proceeds from recent funding will also support regulatory preparations, manufacturing scale-up, and advancement of additional AMP candidates in the pipeline. Unlike traditional antibiotics that target specific bacterial functions, OMN6’s pore-forming mechanism minimizes the chance of resistance development. Since inception, Omnix Medical has raised a total of $43 million to finance its R&D and clinical programs.

Participated · Series C · Sep 2020

keepMed designs and develops keePAP, a hoseless, wearable, responsive and personalized positive airway pressure device that delivers PAP intermittently with minimal airflow by mobilizing the user’s respiratory system. Unlike traditional PAP devices that deliver continuous high-flow air, keePAP provides on-demand pressure only as needed. The company completed CE certification and finished a first-in-human study at the end of 2019. keepMed plans to use proceeds from its recent financing to advance clinical development toward FDA clearance and a market launch in the USA and Europe. The device targets treatment of Obstructive Sleep Apnea, a widespread disorder associated with increased cardiovascular and metabolic risk and major quality-of-life impacts. keepMed is based in Israel and emphasizes a minimally invasive, patient-friendly alternative to conventional PAP therapy. Ninox Medical, founded in 2012 and based in Lyon, France, develops and commercializes a device to treat obstructive sleep apnea. Its core product, the KeePAP™ device, is a small wearable Automatic Positive Airway Pressure (APAP) system that does not require the air blower or mask used in existing solutions. The company is led by CEO Alex Rapoport. Ninox recently completed a $10M Series B financing to support its next growth phase. The funds are earmarked to scale operations, further develop KeePAP™ to obtain CE Mark and 510(k) approvals, reinforce management and technical teams, and build infrastructure for larger clinical trials and commercialization.

Participated · Series C · Nov 2010

Superfish develops algorithmic visual-search technology that analyzes images 100% algorithmically to find similar images in real time without text tags or human intervention. The company applies this technology to enhance the online shopping experience. Founded in 2006 by Adi Pinhas and Michael Chertok and based in Palo Alto, CA, Superfish has raised a $10m Series D. The round was led by Vintage Investment Partners with participation from existing investors DFJ and DFJ Tamir Fishman Ventures. Superfish will use the funds to launch Venn, a photo-discovery and sharing solution. Venn is intended to surface visual patterns and common interests within the social graph. Superfish develops a visual search platform that allows users to use images, rather than keywords, to find other images and related information. In April the company launched Window Shopper, a browser add-on that searches for identical or similar products across thousands of sites, including Amazon, eBay, Best Buy, Target, and Walmart. The company is based in San Mateo, California, and operates research and development in Israel. Superfish raised $4M in a Series C round and previously raised $5.3M in a Series B in 2008. The new capital will be used to expand operations, improve market position, build channel partnerships and enhance product innovation and development.